BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kumar M, Singh A, Kumari S, Kumar P, Wasi M, Mondal AK, Rudramurthy SM, Chakrabarti A, Gaur NA, Gow NAR, Prasad R. Sphingolipidomics of drug resistant Candida auris clinical isolates reveal distinct sphingolipid species signatures. Biochim Biophys Acta Mol Cell Biol Lipids 2021;1866:158815. [PMID: 32942047 DOI: 10.1016/j.bbalip.2020.158815] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Kumari S, Kumar M, Esquivel BD, Wasi M, Pandey AK, Kumar Khandelwal N, Mondal AK, White TC, Prasad R, Gaur NA. Unmasking of CgYor1-Dependent Azole Resistance Mediated by Target of Rapamycin (TOR) and Calcineurin Signaling in Candida glabrata. mBio 2022;:e0354521. [PMID: 35038899 DOI: 10.1128/mbio.03545-21] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Rollin-Pinheiro R, Bayona-Pacheco B, Domingos LTS, da Rocha Curvelo JA, de Castro GMM, Barreto-Bergter E, Ferreira-Pereira A. Sphingolipid Inhibitors as an Alternative to Treat Candidiasis Caused by Fluconazole-Resistant Strains. Pathogens 2021;10:856. [PMID: 34358009 DOI: 10.3390/pathogens10070856] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
3 Dalisay DS, Rogers EW, Molinski TF. Oceanapiside, a Marine Natural Product, Targets the Sphingolipid Pathway of Fluconazole-Resistant Candida glabrata. Mar Drugs 2021;19:126. [PMID: 33652774 DOI: 10.3390/md19030126] [Cited by in F6Publishing: 2] [Reference Citation Analysis]